Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

Although inotuzumab ozogamicin (InO) is recognized as an effective agent in relapsed acute lymphoblastic leukemia (ALL) in adults, data on safety and efficacy in pediatric patients are scarce. We report the use of InO in 51 children with relapsed/refractory ALL treated in the compassionate use progr...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Leukemia
Hlavní autoři: Bhojwani, Deepa, Sposto, Richard, Shah, Nirali N., Rodriguez, Vilmarie, Yuan, Constance, Stetler-Stevenson, Maryalice, O’Brien, Maureen M., McNeer, Jennifer L., Quereshi, Amrana, Cabannes, Aurelie, Schlegel, Paul, Rossig, Claudia, Dalla-Pozza, Luciano, August, Keith, Alexander, Sarah, Bourquin, Jean-Pierre, Zwaan, Michel, Raetz, Elizabeth A., Loh, Mignon L., Rheingold, Susan R.
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6438769/
https://ncbi.nlm.nih.gov/pubmed/30267011
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-018-0265-z
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky